[Source: JAMA, full page: (LINK). Summary, edited.]
Priorities for the US Health Community Responding to COVID-19
Amesh A. Adalja, MD1; Eric Toner, MD1; Thomas V. Inglesby, MD1
Author Affiliations: 1 Johns Hopkins Center for Health Security and the Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
JAMA. Published online March 3, 2020. doi:10.1001/jama.2020.3413
In late December 2019, a cluster of unexplained cases of viral pneumonia occurred in Wuhan, China.1 This initial cluster of patients with what soon became known as coronavirus disease 2019 (COVID-19) heralded the arrival of a new pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, close to 90 000 cases have occurred in more than 60 countries with approximately 3000 deaths. The World Health Organization (WHO) has declared these events a Public Health Emergency of International Concern.
Corresponding Author: Thomas V. Inglesby, MD, Johns Hopkins Bloomberg School of Public Health, 621 E Pratt St, Ste 210, Baltimore, MD 21202 (email@example.com).
Published Online: March 3, 2020. doi:10.1001/jama.2020.3413
Conflict of Interest Disclosures: Dr Adalja reports being a shareholder or investor in Luminex, Roche, Evolent, UPMC, Merck, and Ativa Medical and receiving fees from Merck. No other disclosures were reported.
Keywords: SARS-COV-2; COVID-19; USA.